Coherus Oncology (CHRS) Change in Acquisitions & Divestments (2017 - 2026)

Coherus Oncology (CHRS) has 9 years of Change in Acquisitions & Divestments data on file, last reported at $38.1 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Acquisitions & Divestments changed N/A year-over-year to $38.1 million; the trailing twelve-month figure through Mar 2026 stood at $55.5 million (changed N/A YoY), and the FY2025 full-year result was $21.5 million, up 246.16% from the prior year.
• Change in Acquisitions & Divestments climbed to $38.1 million in Q1 2026, from $19.8 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $131.1 million in Q4 2023 to a low of -$4.2 million in Q2 2023.
• A 4-year average of $26.1 million and a median of $11.8 million in 2023 frame the typical range for Change in Acquisitions & Divestments.
• Across the five-year window, Change in Acquisitions & Divestments sank 101.9% in 2024 and jumped 896.3% in 2025, its largest moves.
• Tracing CHRS's Change in Acquisitions & Divestments over 4 years: stood at $131.1 million in 2023, then slumped by 101.9% to -$2.5 million in 2024, then jumped by 896.3% to $19.8 million in 2025, then surged by 92.48% to $38.1 million in 2026.
• Business Quant data shows CHRS's Change in Acquisitions & Divestments at $38.1 million in Q1 2026, $19.8 million in Q4 2025, and -$2.5 million in Q4 2024.